RSC-BMCS Targeted Protein Degradation: “Three’s a crowd?”
Event
RSC-BMCS Targeted Protein Degradation: “Three’s a crowd?”
Dates
Wednesday 16th – Thursday 17th November 2022
Both days will take place in the afternoon from 1 PM – 5 PM (GMT).
Place
Virtual
Important links
Twitter hashtag – #ProtDeg22
Synopsis
Targeted protein degradation is a rapidly developing field of drug discovery which is expanding the proportion of human proteins which are tractable drug targets. Whereas conventional small molecules are designed to block the activity of a protein, targeted protein degraders act by harnessing biological pathways to remove the protein entirely. This conference will showcase presentations showing the application and development of degradation technologies such as molecular glues and heterobifunctional degraders (e.g. PROTACs)
Who should attend
This conference is aimed at scientists including medicinal and computational chemists, structural and chemical biologists etc., and will be suitable for both those who are experienced in the field of targeted protein degradation and those who are keen to learn more about this rapidly developing field. This new conference is running in a virtual format, and we welcome an international audience of guests and speakers. The sessions are running in the afternoon UK time, and are therefore also easily accessible for a North and South American audience.
Call for Abstracts
Abstract submission is open now. Please click here to submit your oral abstract.
Confirmed Speakers
Driving Drug Discovery by Accelerated Target Degradation
Matt Clifton, Novartis
Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation
Chuck Hendrick, Janssen
VHL SAR-understanding and its influence for PROTAC design
Johannes Krieger, Merck KGaA
Modulation of ADP-ribose Metabolism by Targeted Protein Degradation
Anne-Sophie Marques, University of Oxford
Expansion of the Druggable Genome Through Rational Approaches to Molecular Glue Discovery
Mary Matyskiela, Neomorph
Advances and future opportunities in cereblon-mediated molecular glue
Jennifer Riggs, BMS
PROTACs: Insights into MedChem Design
Markus Schade, AstraZeneca
Haven’t got a glue: emerging rule for the design of molecular glue degraders
Nicolas Thomae, Friedrich Miescher Instiute
Molecular Glue Degraders: From Serendipity to Rational Design
Owen Wallace, CSO, Monte Rosa Therapeutics
Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications
Yi Zhang, Kymera
Registration
Registration is now open, and may be accessed by clicking here. You may pay by card or request an invoice for settlement by bank transfer. Registration fees are:
| RSC Member* | £75.00 |
| Non-member | £110.00 |
| RSC Student** Member* (Undergraduate and Post-Graduate) |
£25.00 |
| Student** Non-Member (Undergraduate and Post-Graduate) |
£50.00 |
Registration closing dates:
Online registration (card payments): Thursday 17th November 2022 at 17:00 (GMT)
Registration against invoice (bank transfers): Friday 14th October 2022 at 17:00 (GMT)
* Member is a paid-up member of the RSC
** Student rates apply to undergraduate and post-graduate students only, but not post-doctoral students.
Programme
Wednesday 16th November
| 13.00 | Welcome & opening remarks |
|---|---|
| 13.10 | (1) Markus Schade, AZ – PROTACs: Insights into MedChem Design |
| 13.50 | (2) Chuck Hendrick, JNJ - Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation |
| 14.30 | BREAK |
| 14.50 | (3) Yi Zhang, Kymera - Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications |
| 15.30 | (4) Matt Clifton, Novartis - Driving Drug Discovery by Accelerated Target Degradation |
| 16.10 | BREAK |
| 16.20 | (5) Mary Matyskiela, Neomorph – Expansion of the Druggable Genome Through Rational Approaches to Molecular Glue Discovery |
| 17.00 | Close |
Thursday 17th November
| 13.00 | Start |
|---|---|
| 13.00 | (1) Anne-Sophie Marques, University of Oxford - Modulation of ADP-ribose Metabolism by Targeted Protein Degradation |
| 13.40 | (2) Johannes Krieger, Merck - VHL SAR-understanding and its influence for PROTAC design |
| 14.20 | BREAK |
| 14.40 | (3) Nicolas Thoma, Friedrich Miescher Institute for Biomedical Research - Haven’t got a glue: emerging rule for the design of molecular glue degraders |
| 15.20 | (4) Owen Wallace, Monte Rosa - Molecular Glue Degraders: From Serendipity to Rational Design |
| 16.00 | BREAK |
| 16.10 | (5) Jennifer Riggs, BMS - Advances and future opportunities in cereblon-mediated molecular glue |
| 16.50 | Closing remarks & end |
Our Exhibitors/Sponsors
We are grateful to our confirmed exhibitors/sponsors for their valued support.
Organising Committee
Adrian Hall, UCB
Katherine Jones (chair), Charles River
Fabian Lecomte (treasurer), Ferring Pharmaceuticals
Secretariat Contact and Further Information
Hg3 Conferences Ltd
+44 (0)1423 529333
E-mail